Source: Annual Congress 2010 - Biomarkers for lung cancer
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
R. Cherneva, O. Georgiev, D. Petrova, M. Stamenova, N. Trifonova (Sofia, Bulgaria). Plasma levels of alpha crystalline antibodies in NSCLC patients – Diagnostic significance. Eur Respir J 2010; 36: Suppl. 54, 3249

Member's Comments

No comment yet.

Related content which might interest you: Tissue expression of alpha crystallins and plasma levels of antibodies against them in NSCLC patients – Prognostic significance Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010 EGFR and hTERT mRNA expression in non-small cell lung cancer patients – Diagnostic and prognostic implications Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010 High levels of serum cholesterol – protective and predictive factor for activation of tuberculosis; practical considerations Source: Annual Congress 2009 - Pulmonary infections Year: 2009 TTF-1 in advanced SCLC – Diagnostic and prognostic relevance Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer Year: 2011 Prognostic significance of plasma D-dimer (DD) in lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 72s Year: 2002 Clinical value of soluble interleukine-2 receptor (sIL-2R) serum level examination in the pulmonary sarcoidosis (PS) Source: Eur Respir J 2003; 22: Suppl. 45, 226s Year: 2003 Clinical decision making in alpha1 antitrypsin deficiency emphysema – Methodologies to determine individual rates of FEV1 decline Source: Annual Congress 2010 - Novel biomarkers and old parameters in approaching pulmonary diseases Year: 2010 Serum procalcitonin level: clinical significance Source: Eur Respir J 2011; 37: 723 Year: 2011 The nuclear expression of the small heat shock protein – alpha B crystalline as a marker for poor prognosis in NSCLC patients Source: Annual Congress 2009 - Basic science and lung cancer Year: 2009 The clinical significance of serum osteoprotegerin (OPG) and pro-gastrin-releasing peptide (ProGRP) concentrations in lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 318s Year: 2004 C-reactive protein in community acquired pneumonia – Correlation with main clinical indices Source: Annual Congress 2012 - Management of severe respiratory infections Year: 2012 Detection of lung cancer on CXR – A comparison of radiologist‘s performance Source: Annual Congress 2010 - Quality management for lung cancer patients Year: 2010 Clinical significance of serum osteopontin levels in lung cancer Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012 Diagnostic value of serum soluble interleukin-2 receptor (SIL- 2R) and acute phase proteins levels (APP) in community acquired pneumonia Source: Eur Respir J 2003; 22: Suppl. 45, 149s Year: 2003 EGFR and hTERT expression in high risk COPD patients – clinical application Source: Annual Congress 2009 - Biological and clinical markers in lung cancer Year: 2009 Monitoring of efficacy of therapy with monoclonal antibodies – Omalizumab – Using the Recovery-ELISA Source: Annual Congress 2011 - Treatment strategies, systemic manifestations and biomarkers in airway diseases Year: 2011 Role of genetic polymorphism in TNF α and TGF β gene in Polish patients with sarcoidosis Source: Annual Congress 2010 - Sarcoidosis: from the bench to the bedside Year: 2010 The clinical significance of serum VEGF C, VEGF D and sVEGFR2 concentration in lung cancer Source: Annual Congress 2007 - Diagnosis and prognosis in thoracic oncology Year: 2007 Clinical evaluation in 14 cases of diffuse alveolar hemorrhage – Relationship between initial findings and prognosis – Source: Annual Congress 2010 - Rare diffuse lung diseases Year: 2010 Adenovirus IgG avidity – A marker of outcome in COPD-exacerbations Source: Annual Congress 2012 - COPD treatment and varia Year: 2012